Inhibition of HIV-1 TAR RNA-Tat peptide complexation using poly(acrylic acid)

Biochemical and Biophysical Research Communications

Volumn 320, Issue 1, 2004, Pages 95-99

  Zhao, Hong ^a   Li, Jinru ^a   Jiang, Long ^a  

^a INSTITUTE OF CHEMISTRY   (China)

Author keywords

Inhibition; Poly(acrylic acid); Quartz crystal microbalance; TAR RNA; Tat peptide

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; POLYACRYLIC ACID; TRANSACTIVATOR PROTEIN; VIRUS RNA;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; GENETIC TRANSCRIPTION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN RNA BINDING; PROTEIN TARGETING; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ACRYLIC RESINS; BINDING SITES; GENE PRODUCTS, TAT; HIV LONG TERMINAL REPEAT; HIV-1; MACROMOLECULAR SUBSTANCES; MOLECULAR WEIGHT; NUCLEIC ACID CONFORMATION; PROTEIN BINDING; RNA, VIRAL;

HUMAN IMMUNODEFICIENCY VIRUS 1; PAA;

EID: 2942659066     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.05.148     Document Type: Article

References (34)

1. Rana T.M., Jeang K.-T. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch. Biochem. Biophys. 365:1999;175-185
2. Cullen B.R. Trans-activation of human immunodeficiency virus occurs via a biomodal mechanism. Cell. 46:1986;973-982
3. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., Gonda M.A., Aldovini A., Debouk C., Gallo R.C., Wong-Staal F. The trans-activator gene of HTLV-III is essential for virus replication. Nature. 320:1986;367-371
4. Carroll R., Martarano L., Derse D. Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 and gene chimeras. J. Virol. 65:1991;3460-3467
5. Tassew N., Thompson M. RNA-peptide binding and the effect of inhibitor and RNA mutation studied by on-line acoustic wave sensor. Anal. Chem. 74:2002;5313-5320
6. Rosen A., Sodroski J.G., Haseltine W.A. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell. 41:1985;813-823
7. Muesing M.A., Smith D.H., Capon D.A. Regulation of mRNA accumulation by virus trans-activator protein. Cell. 48:1987;691-701
8. Dingwall C., Ernberg I., Gait M.J., Green S.M., Heaphy S., Karn J., Lowe A.D., Singh M., Skinner M.A. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J. 9:1990;4145-4153
9. Roy S., Delling U., Chen C.H., Rosen C.A., Sonenberg N. A bulge structure in HIV-1 TAR RNA is required for tat binding and tat-mediated trans-activation. Genes Dev. 4:1990;1365-1373
10. Feng S., Holland E.C. HIV-1 Tat trans-activation requires the loop sequence with TAR. Nature. 34:1988;165-168
11. Cordingley M.G., LaFemina R.L., Callahan P.L., Condra J.H., Sardana V.V., Graham D.J., Nguyen T.M., LeGrow K., Gotlib L., Schlabach A.J., Colonno R.J. Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro. Proc. Natl. Acad. Sci. USA. 87:1990;8985-8989
12. Mujeeb A., Bishop K., Peterlin M., Turck C., Parslow T.G., James T.L. NMR structure of a biologically active peptide containing the RNA-binding domain of human immunodeficiency virus type 1 Tat. Proc. Natl. Acad. Sci. USA. 91:1994;8248-8252
13. Tan R.A., Frankel D. Circular dichroism studies suggest that TAR RNA changes conformational upon specific binding of arginine or guanidine. Biochemistry. 31:1992;10288-10294
14. Hamy F., Felder E.R., Heizmann G., Lazdins J., Aboul-Ela F., Varani G., Karn J., Klimkait T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl. Acad. Sci. USA. 94:1997;3548-3553
15. Mei H.-Y., Mack D.P., Galan A.A., Halim N.S., Heldsinger A., Loo J.A., Moreland D.W., Sannes-Lowery K.A., Sharmeen L., Truong H.N., Czarnik A.W. Discovery of selective, small-molecule inhibitors of RNA complexes - I. The tat protein/TAR RNA complexes required for HIV-1 transcription. Bioorg. Med. Chem. 5:1997;1173-1184
16. Mei H.-Y., Cui M., Heldsinger A., Lemrow S.M., Loo J.A., Sannes-Lowery K.A., Sharmeen L., Czarnik A.W. Inhibitors of protein-RNA complexation that target the RNA: specific recognition of human immunodeficiency virus type 1 TAR RNA by small organic molecules. Biochemistry. 37:1998;14204-14212
17. Jimenez Bueno G., Klimkait T., Gilbert I.H., Simons C. Solid-phase synthesis of diamine and polyamine amino acid derivatives as HIV-1 Tat-TAR binding inhibitors. Bioorg. Med. Chem. 11:2003;87-94
18. Zhao H., Dai D.S., Li J.R., Chen Y., Jiang L. Quantitative study of HIV-1 Tat peptide and TAR RNA interaction inhibited by poly(allylamine hydrochloride). Biochem. Biophys. Res. Commun. 312:2003;351-354
19. Lohr M., Kibler K.V., Zachary I., Jeang K.T., Selwood D.L. Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells. Biochem. Biophys. Res. Commun. 300:2003;609-613
20. Garbesi A., Hamy F., Maffini M., Albrecht G., Klimkait T. TAR-RNA binding by HIV-1 Tat protein is selectively inhibited by its L-enantiomer. Nucleic Acids Res. 26:1998;2886-2890
21. Wyszko E., Barciszewska M.Z., Bald R., Erdmann V.A., Barciszewska J. The specific hydrolysis of HIV-1 TAR RNA element with the anti-TAR hammerhead ribozyme: structural and functional implications. Int. J. Biol. Macromol. 28:2001;373-380
22. Zhao H., Li J.R., Jiang L. Polyamidoamine dendrimers inhibit binding of Tat peptide to TAR RNA. FEBS Lett. 563:2004;241-245
23. Rusnati M., Urbinati C., Caputo A., Possati L., Lortat-Jacob H., Giacca M., Ribatti D., Presta M. Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J. Biol. Chem. 276:2001;22420-22425
24. Tao J.S., Frankel A.D. Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteins. Proc. Natl. Acad. Sci. USA. 90:1993;1571-1575
25. Hamy F., Gelus N., Zeller M., Lazdins J.L., Bailly C., Klimkait T. Blocking HIV replication by targeting Tat protein. Chem. Biol. 7:2000;669-676
26. Rusnati M., Coltrini D., Oreste P., Zoppetti G., Albini A., Noonan D., d'Adda di Fagagna F., Giacca M., Presta M. Interaction of HIV-1 Tat protein with heparin. J. Biol. Chem. 272:1997;11313-11320
27. Rusnati M., Tulipano G., Spillmann D., Tanghetti E., Oreste P., Zoppetti G., Giacca M., Presta M. Multiple interactions of HIV-1 Tat protein with size-defined heparin oligosaccharides. J. Biol. Chem. 274:1999;28198-28205
28. Lapidot A., Ben-Asher E., Eisenstein M. Tetrahydropyrimidine derivatives inhibit binding of a Tat-like, arginine-containing peptide, to HIV TAR RNA in vitro. FEBS Lett. 367:1995;33-38
29. Churcher M.J., Lamont C., Hamy F., Dingwall C., Green S.M., Lowe A.D., Butler P.J.G., Gait M.J., Karn J. High affinity binding of TAR RNA by the human immunodeficiency virus type-1 tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J. Mol. Biol. 230:1993;90-110
30. Bunde R.L., Jarvi E.J., Rosentreter J.J. A piezoelectric method for monitoring formaldehyde induced crosslink formation between poly-lysine and poly-deoxyguanosine. Talanta. 51:2000;159-171
31. Nikura K., Nagata K., Okahata Y. Quantitative detection of protein binding onto DNA by using QCM. Chem. Lett. 1996;863-864
32. Litovchick A., Lapidot A., Eisenstein M., Kalinkovich A., Borkow G. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry. 40:2001;15612-15623
33. Long K.S., Crothers D.M. Interaction of human immunodeficiency virus type 1 Tat-derived peptides with TAR RNA. Biochemistry. 34:1995;8885-8895
34. Sauerbrey G.A. Use a quartz vibrator from weight thin films on a microbalance. Z. Phys. 155:1959;206-210